SYN Stock Forecast 2025-2026
Distance to SYN Price Targets
SYN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Synthetic Biologics (SYN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SYN and similar high-potential opportunities.
Latest SYN Stock Price Targets & Analyst Predictions
SYN has shown a year-to-date change of -31.4% and a 1-year change of -90.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for SYN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYN Analyst Ratings
SYN Price Target Range
Latest SYN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2021 | Maxim Group | Jason McCarthy | Buy | Upgrade | $0.00 |
| Oct 5, 2020 | Maxim Group | Jason McCarthy | Hold | Downgrade | $0.00 |
| May 10, 2018 | Griffin Securities | Hold | Downgrade | $0.00 | |
| Feb 26, 2016 | FBR Capital | Outperform | Initiates | $10.00 | |
| Oct 13, 2015 | RBC Capital | Outperform | Initiates | $8.00 | |
| Aug 25, 2015 | BTIG | Buy | Initiates | $5.00 | |
| Jun 1, 2015 | William Blair | Outperform | Initiates | $12.00 | |
| Mar 16, 2015 | Maxim Group | Jason McCarthy | Hold | Downgrade | $3.00 |
| Sep 30, 2013 | Maxim Group | Jason McCarthy | Buy | Initiates | $3.00 |
| Jun 25, 2013 | Ascendiant Capital | Buy | Initiates | $2.25 |
Synthetic Biologics Inc (SYN) Competitors
The following stocks are similar to Synthetic Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Synthetic Biologics Inc (SYN) Financial Data
Synthetic Biologics Inc has a market capitalization of $14.72M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +8.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Synthetic Biologics Inc (SYN) Business Model
About Synthetic Biologics Inc
Company Information
Sector
Industry
Employees
0
CEO
Country
United States
IPO Year
2006
Website
www.syntheticbiologics.comSynthetic Biologics Inc (SYN) Latest News & Analysis
A company has rebranded to enhance its clinical development strategy for oncolytic viruses, focusing on those optimized for intravenous administration.
The rebranding reflects a focused clinical strategy, enhancing credibility and potential for breakthroughs in cancer treatment, which could drive stock value and investor interest.
Preclinical results show that topotecan treatment improves the oncolytic activity of VCN-01 against retinoblastoma.
Enhanced oncolytic activity of VCN-01 with topotecan suggests potential breakthroughs in retinoblastoma treatment, impacting the biotech stock performance and future funding opportunities.
The DSMC has approved the progression of the study to enroll patients in Cohort 2 after reviewing safety and pharmacokinetic data from Cohort 1.
The DSMC's recommendation to proceed with patient enrollment indicates progress in the clinical trial, which may boost investor confidence and potentially increase stock value for the company involved.
VCN-01 combined with durvalumab shows a favorable safety profile and promising biological activity in treatment, indicating potential for further development.
Positive results for VCN-01 and durvalumab could indicate potential for new cancer therapies, impacting stock valuations and driving interest in biotech investments.
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript
2 years agoSynthetic Biologics, Inc. (NYSE:SYN) held its Q2 2022 earnings call on August 11, 2022, featuring executives including CEO Steven Shallcross and General Director Manel Cascallo.
The earnings call indicates financial performance and strategic insights, which can influence stock valuation and investor sentiment regarding Synthetic Biologics' future prospects.
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
2 years agoThe focus is on advancing a new oncolytic adenovirus platform, which may impact cancer treatment developments and related investments in the biotech sector.
The focus on advancing the oncolytic adenovirus platform suggests potential breakthroughs in cancer treatment, which could drive stock prices and market interest in biotech companies involved.
Frequently Asked Questions About SYN Stock
What is Synthetic Biologics Inc's (SYN) stock forecast for 2025?
Analyst forecasts for Synthetic Biologics Inc (SYN) are not currently available. The stock is trading at $1.20.
Is SYN stock a good investment in 2025?
According to current analyst ratings, SYN has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYN stock?
Price predictions from Wall Street analysts for SYN are not currently available. The stock is trading at $1.20.
What is Synthetic Biologics Inc's business model?
N/A
What is the highest forecasted price for SYN Synthetic Biologics Inc?
Price targets from Wall Street analysts for SYN are not currently available. The stock is trading at $1.20.
What is the lowest forecasted price for SYN Synthetic Biologics Inc?
Price targets from Wall Street analysts for SYN are not currently available. The stock is trading at $1.20.
What is the overall SYN consensus from analysts for Synthetic Biologics Inc?
The overall analyst consensus for SYN is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are SYN stock price projections?
Stock price projections, including those for Synthetic Biologics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
